PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- CRISPR patent decisions could trigger waves globally (Lab Pulse)
- Geneoscopy Receives New York State Department of Health Permit, Expanding Ability to Provide Laboratory Services Nationwide (Business Wire)
- Opinion How ‘obesity first’ health care is transforming medicine (The Washington Post)
- Remote-controlled robot is changing the game for endoscopes (Advanced Science News)
- 5 notes on the future of GI growth (Becker’s GI & Endoscopy)
- Blue Cross Blue Shield Of Massachusetts Encourages Members To Discuss Colorectal Cancer Screening With Their Doctor (Blue Cross Blue Shield of Massachusetts)
- Biosimilar costs escalate for GI practices (AGA)
- Fourth Ustekinumab Biosimilar, Otulfi, Approved in US (AJMC)